VetSheet

푸로세미드

Furosemide

4-chloro-2-(furan-2-ylmethylamino)-5-sulfamoylbenzoic acid

루프 이뇨제POIVIMSC고양이소형 포유류페렛파충류

다른 이름: Lasix · Salix · Disal · Dimazon · Frusecare · Frusedale · Libeo · Frusol · frusemide · furosemidum · LB-502

VetSheet 수의사 팀 검수업데이트 2026년 4월 5일근거 기반 수의학 참고자료

감사 완료 v13 용량 근거

구조화 용량 계산 근거

Injection

2.75–5.5 mg/kgIVIM

인증된 수의사 확인 필요

복합 일정 조건 — 모두 적용

  • q12-24h
  • q6-8h

NA

반드시 함께 고려할 임상 맥락 (2)
  • NOTE: Watch units closely when calculating doses. Do not confuse CRI dosages using mg/kg/hour with μg/kg/minute.
  • Furosemide injection should be stored at room temperature. A precipitate may form if the injection is refrigerated, but it will resolubilize when warmed without alteration in potency. The human injection (10 mg/mL) should not be used if it has a yellow color. The veterinary injection (50 mg/mL) normally has a slight yellow color.
고위험인증된 수의사 확인 필요formulary프로토콜 2023감사 dose-audit-plumb-v13

Adjunctive therapy for systemic hypertension

1–4 mg/kgPO
  • q8-24h

NA

반드시 함께 고려할 임상 맥락 (3)
  • NOTE: Watch units closely when calculating doses. Do not confuse CRI dosages using mg/kg/hour with μg/kg/minute.
  • ■ Furosemide may be given with or without food. If your animal vomits or acts sick after receiving this medicine on an empty stomach, try giving the next dose with food or a small treat. If vomiting continues, contact your veterinarian.
  • Store furosemide protected from light at room temperature up to 25°C (77°F). Furosemide tablets should be protected from moisture and stored in light-resistant, well-closed containers. Tablets may discolor with exposure to light, and discolored tablets should be discarded. The oral solution should be stored at room temperature and protected from light and freezing; discard opened bottles after 90 days.
formulary프로토콜 2023감사 dose-audit-plumb-v13

용량은 수의사 전문가를 위한 임상 참고자료입니다. 반드시 최신 약물 정보 및 개별 환자에 따라 확인하시기 바랍니다.

진료 중이신가요? VetSheet의 AI가 약물, 용량, 투여 기간을 구조화된 진료 기록에 바로 기입합니다.VetSheet 작동 방식 보기

개요

푸로세미드는 강력하고 속효성인 ​루프 이뇨제​로 수의학에서 체액 과부하 상태를 관리하는 데 널리 사용됩니다. 여러 동물 종에서 ​울혈성 심부전(CHF)​​폐부종​ 치료의 핵심 약물입니다. 강력한 이뇨 작용을 촉진하여 심장의 전부하를 빠르게 감소시키고 정맥 울혈을 완화합니다.

주요 심장 질환 적용 외에도 푸로세미드는 다음 용도로 사용됩니다:

  • ​핍뇨성 신부전:​ 핍뇨를 다뇨로 전환하고 소변 흐름을 촉진하기 위해.
  • ​고칼슘혈증:​ 신장의 칼슘 배설을 촉진하기 위해 (사전 체액 확장이 필요함).
  • ​운동 유발성 폐출혈(EIPH):​ 경주마에서 비출혈을 줄이기 위한 예방적 사용.
  • ​유방 부종:​ 소의 분만 후 사용을 위해 FDA 승인됨.

강력한 효능으로 인해 푸로세미드는 심각한 체액 및 전해질 변화를 유발할 수 있으므로 수화 상태와 혈청 전해질(특히 칼륨)을 주의 깊게 모니터링해야 합니다.

작용 기전

Furosemide acts primarily on the thick ascending limb of the loop of Henle in the nephron.

  • ​Inhibition of NKCC2:​ It reversibly binds to and inhibits the Na⁺/K⁺/2Cl⁻ cotransporter on the luminal membrane → prevents the reabsorption of sodium, potassium, and chloride.
  • ​Loss of Medullary Hypertonicity:​ This disruption abolishes the hypertonic medullary interstitium → impairs the kidney's ability to concentrate urine → results in profound, dose-dependent diuresis.
  • ​Electrolyte Excretion:​ It significantly increases the renal excretion of water, Na⁺, K⁺, Cl⁻, Ca²⁺, Mg²⁺, H⁺, NH₄⁺, and bicarbonate.
  • ​Hemodynamic Effects:​ Furosemide induces mild renal venodilation and transiently increases glomerular filtration rate (GFR) via prostaglandin release. This venodilation provides rapid relief in acute cardiogenic pulmonary edema, often before the onset of significant diuresis.

안전성·주의사항

금기사항

  • Anuria
  • Hypersensitivity to furosemide
  • Progressive renal disease if increasing azotemia and oliguria occur during therapy
  • Seriously depleted electrolytes
  • Severe dehydration
  • Severe electrolyte depletion
  • Hepatic coma
  • Pericardial effusion where cardiac tamponade is confirmed

부작용

  • Fluid and electrolyte abnormalities (hyponatremia, hypokalemia, hypocalcemia, hypomagnesemia)
  • Prerenal azotemia (secondary to dehydration)
  • Ototoxicity (especially in cats with high-dose IV therapy)
  • Gastrointestinal distress
  • Hematologic effects (anemia, leukopenia)
  • Weakness and restlessness
  • Hypokalaemia
  • Hypochloraemia
  • Hypocalcaemia
  • Hypomagnesaemia
  • Hyponatraemia
  • Polyuria/polydipsia (PU/PD)
  • Prerenal azotaemia
  • Gastrointestinal disturbances
  • Leucopenia
  • Anaemia
  • Electrolyte depletion (hypokalemia, hyponatremia, hypochloremia)
  • Polyuria and polydipsia

주의

Use with caution in patients with pre-existing electrolyte or water balance abnormalities, impaired hepatic function (may precipitate hepatic coma), and diabetes mellitus. Monitor carefully in patients with conditions leading to fluid loss (e.g., vomiting, diarrhea). Patients hypersensitive to sulfonamides may also be hypersensitive to furosemide. Ensure animals have normal food and water intake to prevent imbalances.

약물 상호작용

ACE INHIBITORS (e.g., enalapril, benazepril)

Increased risks for hypotension, particularly in patients who are volume or sodium depleted secondary to diuretics

AMINOGLYCOSIDES (gentamicin, amikacin, etc.)

Increased risk for ototoxicity

AMPHOTERICIN B

Loop diuretics may increase the risk for nephrotoxicity development; hypokalemia

CORTICOSTEROIDSModerate

Increased risk for GI ulceration; hypokalemia

DIGOXINMajor

Furosemide-induced hypokalemia may increase the potential for digoxin toxicity

INSULIN

Furosemide may alter insulin requirements

MUSCLE RELAXANTS, NON-DEPOLARIZING (e.g., atracurium, tubocurarine)

Furosemide may prolong neuromuscular blockade

PROBENECID

Furosemide can reduce uricosuric effects

SALICYLATES

Loop diuretics can reduce the excretion of salicylates

SUCCINYLCHOLINE

Furosemide may potentiate effects

THEOPHYLLINEModerate

Pharmacologic effects of theophylline may be enhanced when used with furosemide

AminoglycosidesMajor

Potentiates nephrotoxicity and ototoxicity

AcetazolamideModerate

Increased risk of hypokalaemia

ThiazidesModerate

Increased risk of hypokalaemia

NSAIDsMajor

Decreased diuretic efficacy and predisposes to nephrotoxicity, particularly with poor renal perfusion

TubocurarineModerate

Inhibits muscle relaxation qualities

SuxamethoniumModerate

Increases the effects of suxamethonium

ACE Inhibitors (e.g., Benazepril, Enalapril)Moderate

Increased risk of hypotension and renal impairment; however, concurrent use is standard of care for heart failure with appropriate monitoring.

Aminoglycosides (e.g., Gentamicin)Major

Increased risk of ototoxicity and nephrotoxicity.

모니터링

  • Serum electrolytes (especially potassium, sodium, calcium, magnesium)
  • Blood glucose
  • Hydration status
  • Blood pressure, if indicated
  • Clinical signs of edema, patient weight, if indicated
  • Evaluation of ototoxicity, particularly with prolonged therapy or in cats
  • Resting respiratory rate (at home by owner)
  • Serum electrolytes (Potassium, Sodium, Chloride, Calcium, Magnesium)
  • Renal parameters (BUN, Creatinine)
  • Clinical signs of ototoxicity (especially in cats)
  • Serum electrolytes (especially Potassium, Sodium, Chloride)
  • Renal function (BUN, Creatinine)
  • Clinical signs of edema/heart failure resolution

약동학

반감기

고양이1-2 hours1-1.5 hours

흡수

In dogs, oral bioavailability is approximately 77%. In humans, 60-75% absorbed following oral administration. Diuretic effect takes place within 5 minutes after IV administration and within 1 hour after oral dosing. Peak effects occur ~30 minutes after IV and 1-2 hours after PO.

분포

Approximately 95% bound to plasma proteins in both azotemic and normal patients.

대사

Undergoes some hepatic metabolism (glucuronidation).

배설

Excreted primarily via the kidneys.

과다투여

The LD50 in dogs after oral administration is >1000 mg/kg; after IV injection >300 mg/kg. Chronic overdosing at 10 mg/kg for six months in dogs led to development of calcification and scarring of the renal parenchyma.

Acute overdosage may cause severe electrolyte and water balance problems, CNS effects (ranging from lethargy to coma and seizures), and cardiovascular collapse.

​Treatment:​

  • Empty the gut after recent oral ingestion using standard protocols.
  • Avoid concomitant cathartics as they may exacerbate fluid and electrolyte imbalances.
  • Aggressively monitor and treat electrolyte and water balance abnormalities supportively.
  • Monitor respiratory, CNS, and cardiovascular status.

제품

제형

  • Oral Solution (Syrup)
  • Injection
  • Oral tablets
  • Injectable solution (IV/IM/SC)
  • Injectable: 50 mg/ml solution
  • Oral: 10 mg tablet
  • Oral: 20 mg tablet
  • Oral: 40 mg tablet
  • Oral: 20 mg/5 ml sugar-free solution
  • Oral: 40 mg/5 ml sugar-free solution
  • Oral: 50 mg/5 ml sugar-free solution

동물용의약품

  • Furosemide Tablets: 12.5 mg, & 50 mg; Salix, Disal, generic
  • Furosemide Oral Solution (Syrup): 10 mg/mL in 60 mL; generic
  • Furosemide for Injection: 50 mg/mL (5%) in 50 mL & 100 mL vials; Disal Injection, Salix Injection, generic
  • Dimazon 10 mg, 50 mg tablets
  • Dimazon 5% injectable solution
  • Frusecare 40 mg tablets
  • Frusedale 40 mg tablets
  • Libeo 10 mg, 40 mg chewable tablets

인용의약품

  • Furosemide Oral Tablets: 20 mg, 40 mg, & 80 mg; Lasix; generic
  • Furosemide Oral Solution: 10 mg/mL in 60 mL & 120 mL; 40 mg/5 mL in 500 mL & UD 5 mL & 10 mL; generic
  • Furosemide Injection: 10 mg/mL in 2 mL (20 mg), 4 mL (40 mg) & 10 mL (100 mg) single-dose vials; generic
  • Lasix 20 mg, 40 mg tablets
  • Lasix oral solution
  • Lasix injectable solution
  • Frusol

규제 현황

European Union✓ 승인됨처방전의약품EMA
🐕 Dogs🐈 Cats

POM-V classification in the UK.

United Kingdom✓ 승인됨처방전의약품VMD
🐕 Dogs🐈 Cats

POM-V, POM.

규제 데이터 없음: 🇺🇸 US · 🇭🇰 HK · 🇹🇼 TW · 🇯🇵 JP · 🇰🇷 KR · 🇦🇺 AU

보관·안정성

Tablets should be stored in light-resistant, well-closed containers. Oral solution should be stored at room temperature and protected from light and freezing. Injection should be stored at room temperature. A precipitate may form if the injection is refrigerated, but will resolubilize when warmed without alteration in potency. Unstable at an acid pH, but very stable under alkaline conditions.

보호자 정보

푸로세미드(일반적으로 라식스라는 상품명으로 알려짐)는 반려동물의 체내에 과도하게 축적된 수분을 배출하도록 돕는 강력한 ​이뇨제​입니다. 심부전이나 폐에 물이 차는 증상에 가장 흔하게 처방됩니다.

​중요:​ 이 약은 체내에서 수분을 제거하기 때문에 반려동물의 소변 횟수와 양이 크게 증가합니다. 심각한 탈수를 예방하기 위해 ​반려동물이 항상 신선한 물을 마음껏 마실 수 있도록 해주세요​.

  • ​가정에서의 모니터링:​ 반려동물이 심장 질환 치료를 받고 있다면, 수의사가 반려동물의 ​안정 시 호흡수​(수면 중 1분당 호흡수)를 측정해 달라고 요청할 수 있습니다. 이는 약물 용량이 적절한지 확인하는 매우 중요한 도구입니다.
  • ​수의사에게 연락해야 할 때:​ 과도한 갈증, 극심한 무기력, 쇠약, 안절부절못함, 소변량 감소, 구토 또는 매우 빠른 심박수 등 탈수나 전해질 불균형의 징후를 발견하면 즉시 수의사에게 연락하십시오.
  • ​투약:​ 수의사의 투약 지시를 정확히 따르십시오. 체액 제거와 탈수 유발 사이의 균형은 매우 민감하므로 수의사와 상의 없이 임의로 용량을 변경하지 마십시오.

VetSheet 의약품 참고자료는 수의사 전문가의 임상 의사결정 지원을 위한 것이며, 전문적 판단이나 제조사의 최신 약물 정보를 대체할 수 없습니다.